• A SE, Moses PD, George R 2005 Ocular manifestations of Behcet's disease. Indian Pediatr. 42: 942-945. *

• Aeberli D, Oertle S, Mauron H, Reichenbach S, Jordi B, Villiger PM 2002 Inhibition of the TNF-pathway: use of infliximab and etanercept as remission-inducing agents in cases of therapy-resistant chronic inflammatory disorders. Swiss Med. Wkly. 132: 414-422. *

• Ahmad T, Wallace GR, James T, Neville M, Bunce M, Mulcahy-Hawes K, Armuzzi A, Crawshaw J, Fortune F, Walton R, Stanford MR, Welsh KI, Marshall SE, Jewell DP 2003 Mapping the HLA association in Behcet's disease: a role for tumor necrosis factor polymorphisms? Arthritis Rheum. 48: 807-813. *

• Ahmad T, Zhang L, Gogus F, Verity D, Wallace G, Madanat W, Fayyad F, James T, Neville M, Kanawati C, Fortune F, Celik A, Stanford M, Jewell DP, Marshall SE 2005 CARD15 polymorphisms in Behcet's disease. Scand. J. Rheumatol. 34: 233-237.

• Ahn JK, Park YG 2007 Human leukocyte antigen B27 and B51 double-positive Behcet uveitis. Arch. Ophthalmol. 125: 1375-1380. *

• Akay N, Boyvat A, Heper AO, Soykan I, Arica IE, Bektas M, Ensari A, Cokca F 2006 Behcet's disease-like presentation of bullous pyoderma gangrenosum associated with Crohn's disease. Clin. Exp. Dermatol. 31: 384-386. *

• Akman A, Kacaroglu H, Donmez L, Bacanli A, Alpsoy E 2007 Relationship between periodontal findings and Behcet's disease: a controlled study. J. Clin. Periodontol. 34: 485-491. *

• Akman A, Kankavi O, Ciftcioglu MA, Alpsoy E 2008 Surfactant proteins in inflammatory skin diseases: controlled study. Arch. Dermatol. Res. 300: 353-356. *

• Akman A, Sallakci N, Coskun M, Bacanli A, Yavuzer U, Alpsoy E, Yegin O 2006 TNF-alpha gene 1031 T/C polymorphism in Turkish patients with Behcet's disease. Br. J. Dermatol. 155: 350-356. *

• Akman A, Sallakci N, Kacaroglu H, Tosun O, Yavuzer U, Alpsoy E, Yegin O 2008 Relationship between periodontal findings and the TNF-alpha gene 1031T/C polymorphism in Turkish patients with Behcet's disease. J. Eur. Acad. Dermatol. Venereol. Mar 18 [Epub ahead of print]. *

• Akpolat T, Koc Y, Yeniay I, Akpek G, Gullu I, Kansu E, Kiraz S, Ersoy F, Batman F, Kansu T, et al 1992 Familial Behcet's disease. Eur. J. Med. 1: 391-395.

• Al-Mutawa SA, Hegab SM 2004 Behcet's disease. Clin. Exp. Med. 4: 103-131. *

• Al-Otaibi LM, Porter SR, Poate TW 2005 Behcet's disease: a review. J. Dent. Res. 84: 209-222. *

• Alayli G, Aydin F, Coban AY, Sullu Y, Canturk F, Bek Y, Durupinar B, Canturk T 2007 T helper 1 type cytokines polymorphisms: association with susceptibility to Behcet's disease. Clin. Rheumatol. 26: 1299-1305. *

• Albrecht J, Atzeni F, Baldini C, Bombardieri S, Dalakas MC, Demirkesen C, Yazici H, Mat C, Werth VP, Sarzi-Puttini P 2006 Skin involvement and outcome measures in systemic autoimmune diseases. Clin. Exp. Rheumatol. 24: S52-S59.

• Alexis AF, Strober BE 2005 Off-label dermatologic uses of anti-TNF-a therapies. J. Cutan. Med. Surg. 9: 296-302.

• Almoznino G, Ben-Chetrit E 2007 Infliximab for the treatment of resistant oral ulcers in Behcet's disease: a case report and review of the literature. Clin. Exp. Rheumatol. 25: S99-S102.

• Alpsoy E, Yilmaz E, Coskun M, Savas A, Yegin O 1998 HLA antigens and linkage disequilibrium patterns in Turkish Behcet's patients. J. Dermatol. 25: 158-162.

• Amberger M, Groll S, Gunaydin I, Deuter C, Vonthein R, Kotter I 2007 Intracellular cytokine patterns in Behcet's disease in comparison to ankylosing spondylitis - influence of treatment with interferon-alpha2a. Clin. Exp. Rheumatol. 25: S52-S57.

• Amoura Z, Dode C, Hue S, Caillat-Zucman S, Bahram S, Delpech M, Grateau G, Wechsler B, Piette JC 2005 Association of the R92Q TNFRSF1A mutation and extracranial deep vein thrombosis in patients with Behcet's disease. Arthritis Rheum. 52: 608-611. *

• Antar KA, Keiser HD, Peeva E 2005 Relapsing arterial aneurysms in juvenile Behcet's disease. Clin. Rheumatol. 24: 72-75. *

• Aouba A 2008 Behcet's disease. Rev. Prat. 58: 533-540.

• Apan TZ, Gursel R, Dolgun A 2007 Increased seropositivity of Helicobacter pylori cytotoxin-associated gene-A in Behcet's disease. Clin. Rheumatol. 26: 885-889. *

• Arayssi T, Hamdan A 2004 New insights into the pathogenesis and therapy of Behcet's disease. Curr. Opin. Pharmacol. 4: 183-188.

• Aries PM, Witte T, Lamprecht P 2007 Report on the 34th Meeting of the German Clinical Immunology Workgroup, Frankfurt, 03.-04.11.2006. Z. Rheumatol. 66: 63-64.

• Asarch A, Barak O, Loo DS, Gottlieb AB 2008 Th17 cells: a new therapeutic target in inflammatory dermatoses. J. Dermatolog. Treat. Jul 14 [Epub ahead of print].

• Atalay A, Yildiz-Demirtepe S, Tatlipinar S, Sanli-Erdogan B, Cobankara V, Yildirim C, Bagci H, Atalay EO 2008 HLA-B51 gene and its expression in association with Behcet's disease in Denizli province of Turkey. Mol. Biol. Rep. 35: 345-349. *

• Atsumi T, Amengual O, Yasuda S, Koike T 2004 Antiprothrombin antibodies-are they worth assaying? Thromb. Res. 114: 533-538. *

• Atzeni F, Boiardi L, Casali B, Farnetti E, Sarzi-Puttini P, Pipitone N, Olivieri I, Cantini F, Salvi F, La Corte R, Triolo G, Filippini D, Paolazzi G, Salvarani C 2007 Lack of association of the 463 G/A myeloperoxidase promoter polymorphism with Behcet's disease in Italian patients. Rheumatology (Oxford) 46: 1547-1550.

• Atzeni F, Sarzi-Puttini P, Doria A, Iaccarino L, Capsoni F 2005 Potential off-label use of infliximab in autoimmune and non-autoimmune diseases: a review. Autoimmun. Rev. 4: 144-152.

• Aydin F, Kara N, Senturk N, Gunes S, Canturk M, Bagci H, Bek Y, Turanli A 2007 Lack of association between leptin G2548A gene polymorphism and Behcet's disease. J. Eur. Acad. Dermatol. Venereol. 21: 68-71.

• Aydin G, Keles I, Atalar E, Orkun S 2005 Extensive erosive arthropathy in a patient with Behcet's disease: case report. Clin. Rheumatol. 24: 645-647.

• Ayesh S, Abu-Rmaileh H, Nassar S, Al-Shareef W, Abu-Libdeh B, Muhanna A, Al-Kafri F 2008 Molecular analysis of MEFV gene mutations among Palestinian patients with Behcet's disease. Scand. J. Rheumatol. Jun 26 [Epub ahead of print].

• B'chir Hamzaoui S, Harmel A, Bouslama K, Abdallah M, Ennafaa M, M'rad S, Ben Dridi M; le groupe tunisien d'etude sur la maladie de Behcet 2006 Behcet's disease in Tunisia. Clinical study of 519 cases. Rev. Med. Interne. 27: 742-750.

• Bacanli A, Sallakci N, Yavuzer U, Alpsoy E, Yegin O 2006 Toll-like receptor 2 Arg753Gln gene polymorphism in Turkish patients with Behcet's disease. Clin. Exp. Dermatol. 31: 699-701. *

• Bacon PA 1991 Vasculitic syndromes associated with other rheumatic conditions and unclassified systemic vasculitis. Curr. Opin. Rheumatol. 3: 56-61.

• Baranathan V, Stanford MR, Vaughan RW, Kondeatis E, Graham EM, Fortune F, Madanat W, Kanawati C, Ghabra M, Murray PI, Wallace GR 2007 The association of the PTPN22 620W polymorphism with Behcet's Disease. Ann. Rheum. Dis. 66: 1531-1533.

• Baughman RP, Bradley DA, Lower EE 2005 Infliximab in chronic ocular inflammation. Int. J. Clin. Pharmacol. Ther. 43: 7-11.

• Bayraktar Y, Balkanci F, Bayraktar M, Calguneri M 1997 Budd-Chiari syndrome: a common complication of Behcet's disease. Am. J. Gastroenterol. 92: 858-862.

• Becker MD, Smith JR, Max R, Fiehn C 2005 Management of sight-threatening uveitis: new therapeutic options. Drugs 65: 497-519.

• Berlit P 2007 Neuropsychiatric disease in collagen vascular diseases and vasculitis. J. Neurol. 254 Suppl. 2: II87-II89.

• Berlit P, Stueper B, Fink I, Rebmann V, Hoyer P, Kreuzfelder E, Grosse-Wilde H 2005 Behcet's disease is associated with increased concentrations of antibodies against phosphatidylserine and ribosomal phosphoproteins. Vasa 34: 176-180.

• Bettencourt A, Pereira C, Carvalho L, Carvalho C, Patto JV, Bastos M, Silva AM, Barros R, Vasconcelos C, Paiva P, Costa L, Costa PP, Mendonca D, Correia J, Silva BM 2008 New insights of HLA class I association to Behcet's disease in Portuguese patients. Tissue Antigens Jul 4 [Epub ahead of print]. *

• Blanco P, Viallard JF, Pellegrin JL, Moreau JF 2005 Cytotoxic T lymphocytes and autoimmunity. Curr. Opin. Rheumatol. 17: 731-734.

• Boiardi L, Salvarani C, Casali B, Olivieri I, Ciancio G, Cantini F, Salvi F, Malatesta R, Govoni M, Trotta F, Filippini D, Paolazzi G, Nicoli D, Farnetti E, Macchioni L 2001 Intercellular adhesion molecule-1 gene polymorphisms in Behcet's disease. J. Rheumatol. 28: 1283-1287.

• Borhani-Haghighi A, Samangooie S, Ashjazadeh N, Nikseresht A, Shariat A, Yousefipour G, Safari A 2006 Neurological manifestations of Behcet s disease. Saudi Med. J. 27: 1542-1546.

• Briani C, Doria A, Marcolongo R, Tognon S, Ruggero S, Toffanin E, Ermani M, Ghirardello A, Zampieri S, Semenzato G 2006 Increased titres of IgM anti-heparan sulfate antibody in Behcet's disease. Clin. Exp. Rheumatol. 24: S104-S107.

• Brik R, Gepstein V, Shahar E, Goldsher D, Berkovitz D 2007 Tumor necrosis factor blockade in the management of children with orphan diseases. Clin. Rheumatol. 26: 1783-1785. *

• Bruyn GA 1998 Thalidomide (Celgene Corp.). IDrugs 1: 490-500.

• Burrows NP, Zhao MH, Norris PG, Lockwood CM 1996 ANCA associated with Behcet's disease. J. R. Soc. Med. 89: 47P-48P. *

• Bye L, Modi N, Stanford MR, Kondeatis E, Vaughan R, Fortune F, Kanawati C, Ben-Chetrit E, Ghabra M, Murray PI, Wallace GR 2008 CTLA-4 polymorphisms are not associated with ocular inflammatory disease. Tissue Antigens 72: 49-53. *

• Calabrese L, Resztak K 1998 Thalidomide revisited: pharmacology and clinical applications. Expert Opin. Investig. Drugs 7: 2043-2060.

• Canataroglu A, Tanriverdi K, Inal T, Seydaoglu G, Arslan D, Ozbek S, Baslamisli F 2003 Methylenetetrahydrofolate reductase gene C677T mutation and plasma homocysteine level in Behcet's disease. Rheumatol. Int. 23: 236-240. *

• Cattan D 2005 MEFV mutation carriers and diseases other than familial Mediterranean fever: proved and non-proved associations; putative biological advantage. Curr. Drug Targets Inflamm. Allergy 4: 105-112.

• Chamberlain MA 1978 A family study of Behcet's syndrome. Ann. Rheum. Dis. 37: 459-465. *

• Chang HK, Jang WC, Park SB, Nam YH, Lee SS, Park YW, Kim SK 2007 The novel -G646A polymorphism of the TNFalpha promoter is associated with the HLA-B51 allele in Korean patients with Behcet's disease. Scand. J. Rheumatol. 36: 216-221.

• Chau EM 2007 Aortitis. Curr. Treat. Options Cardiovasc. Med. 9: 109-114.

• Chen X, Katoh Y, Nakamura K, Oyama N, Kaneko F, Endo Y, Fujita T, Nishida T, Mizuki N 2006 Single nucleotide polymorphisms of Ficolin 2 gene in Behcet's disease. J. Dermatol. Sci. 43: 201-205.

• Cheng L, Zhang SZ, Xiao CY, Hou YP, Li L, Luo HC, Jiang HY, Zuo WQ 2000 The A5.1 allele of the major histocompatibility complex class I chain-related gene A is associated with psoriasis vulgaris in Chinese. Br. J. Dermatol. 143: 324-329.

• Chessman D, Kostenko L, Lethborg T, Purcell AW, Williamson NA, Chen Z, Kjer-Nielsen L, Mifsud NA, Tait BD, Holdsworth R, Almeida CA, Nolan D, Macdonald WA, Archbold JK, Kellerher AD, Marriott D, Mallal S, Bharadwaj M, Rossjohn J, McCluskey J 2008 Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity. Immunity 28: 822-832. *

• Chi W, Zhu X, Yang P, Liu X, Lin X, Zhou H, Huang X, Kijlstra A 2008 Upregulated IL-23 and IL-17 in Behcet patients with active uveitis. Invest. Ophthalmol. Vis. Sci. 49: 3058-3064.

• Ching DW, McClintock A, Beswick F 2003 Successful treatment with low-dose thalidomide in a patient with both Behcet's disease and complex regional pain syndrome type I: case report. J. Clin. Rheumatol. 9: 96-98.

• Chmaisse HN, Fakhoury HA, Salti NN, Makki RF 2006 The ICAM-1 469 T/C gene polymorphism but not 241 G/A is associated with Behcets disease in the Lebanese population. Saudi Med. J. 27: 604-607.

• Cho SB, Chun EY, Bang D, Lee KH, Lee ES, Lee S 2005 Coexistence of Behcet's disease and autoimmune disease: clinical features of 11 cases. J. Dermatol. 32: 614-616.

• Cobellis L, Pecori E, Rigatti F, Rotondi M, Scaffa C, De Lucia E, Messalli EM 2007 Therapeutic alternatives in Behcet's syndrome. Clin. Exp. Obstet. Gynecol. 34: 151-153.

• Cohen R, Metzger S, Nahir M, Chajek-Shaul T 2002 Association of the MIC-A gene and HLA-B51 with Behcet's disease in Arabs and non-Ashkenazi Jews in Israel. Ann. Rheum. Dis. 61: 157-160. *

• Colak R, Ozkan Y, Cengiz S, Saral Y, Kandi B, Halifeoglu I 2006 A comparison between the effects of low (1 microg) and standard dose (250 microg) ACTH stimulation tests on adrenal cortex functions with Behcet's disease. J. Eur. Acad. Dermatol. Venereol. 20: 721-725. *

• Coskun M, Bacanli A, Sallakci N, Alpsoy E, Yavuzer U, Yegin O 2005 Specific interleukin-1 gene polymorphisms in Turkish patients with Behcet's disease. Exp. Dermatol. 14: 124-129. *

• Cuchacovich M, Merino G, Yamamoto JH, Villarroel F, Saavedra T, Jofre S, Gatica H, Velasquez V, Pizzo SV, Gonzalez-Gronow M 2005 Behcet's disease patients present high levels of deglycosylated anti-lipoteichoic acid IgG and high IL-8 production after lipoteichoic acid stimulation. Clin. Exp. Rheumatol. 23: S27-S34.

• Curnow SJ, Pryce K, Modi N, Knight B, Graham EM, Stewart JE, Fortune F, Stanford MR, Murray PI, Wallace GR 2008 Serum cytokine profiles in Behcet's disease: is there a role for IL-15 in pathogenesis? Immunol. Lett. Aug 12 [Epub ahead of print].

• Daikeler T, Kotter I, Bocelli Tyndall C, Attarbaschi A, Apperley J, Guardiola P, Gratwohl A, Jantunen E, Marmont A, Porretto F, Musso M, Maurer B, Rinaldi N, Saccardi R, Tyndall A 2007 Haematopoietic stem cell transplantation for vasculitis including Behcet's disease and polychondritis. A retrospective analysis of patients recorded to the European Bone Marrow Transplantation (EBMT) and European League Against Rheumatism (EULAR) … Ann. Rheum. Dis. 66: 202-207. *

• Deitch HR, Huppert J, Adams Hillard PJ 2004 Unusual vulvar ulcerations in young adolescent females. J. Pediatr. Adolesc. Gynecol. 17: 13-16.

• Delunardo F, Conti F, Margutti P, Alessandri C, Priori R, Siracusano A, Rigano R, Profumo E, Valesini G, Sorice M, Ortona E 2006 Identification and characterization of the carboxy-terminal region of Sip-1, a novel autoantigen in Behcet's disease. Arthritis Res. Ther. 8: R71. *

• Deng L, Ding W, Granstein RD 2003 Thalidomide inhibits tumor necrosis factor-alpha production and antigen presentation by Langerhans cells. J. Invest. Dermatol. 121: 1060-1065. *

• Deuter CM, Kotter I, Wallace GR, Murray PI, Stubiger N, Zierhut M 2008 Behcet's disease: ocular effects and treatment. Prog. Retin. Eye Res. 27: 111-136.

• Dhifallah IB, Houman H, Khanfir M, Hamzaoui K 2008 Endothelial nitric oxide synthase gene polymorphism is associated with Behcet's disease in Tunisian population. Hum. Immunol. Aug 15 [Epub ahead of print].

• Direskeneli H, Ergun T, Yavuz S, Hamuryudan V, Eksioglu-Demiralp E 2008 Thalidomide has both anti-inflammatory and regulatory effects in Behcet's disease. Clin. Rheumatol. 27: 373-375. *

• Direskeneli H, Saruhan-Direskeneli G 2003 The role of heat shock proteins in Behcet's disease. Clin. Exp. Rheumatol. 21: S44-S48.

• Do JE, Kwon SY, Park S, Lee ES 2008 Effects of vitamin D on expression of Toll-like receptors of monocytes from patients with Behcet's disease. Rheumatology (Oxford) 47: 840-848.

• Durrani K, Papaliodis GN 2008 The genetics of Adamantiades-Behcet's disease. Semin. Ophthalmol. 23: 73-79.

• Duymaz-Tozkir J, Gul A, Uyar FA, Ozbek U, Saruhan-Direskeneli G 2003 Tumour necrosis factor-alpha gene promoter region -308 and -376 G-->A polymorphisms in Behcet's disease. Clin. Exp. Rheumatol. 21: S15-S18.

• Duymaz-Tozkir J, Yilmaz V, Uyar FA, Hajeer AH, Saruhan-Direskeneli G, Gul A 2005 Polymorphisms of the IL-8 and CXCR2 genes are not associated with Behcet's disease. J. Rheumatol. 32: 93-97.

• Duzgun N, Duman T, Morris Y, Tutkak H, Kose K, Ertugrul E, Aydintug OT 2008 Thymidylate synthase genotype and serum concentrations of homocysteine and folate in Behcet's disease Clin. Rheumatol. 27: 1221-1225.

• Elezoglou A, Kafasi N, Kaklamanis PH, Theodossiadis PG, Kapsimali V, Choremi E, Vaiopoulos G, Sfikakis PP 2007 Infliximab treatment-induced formation of autoantibodies is common in Behcet's disease. Clin. Exp. Rheumatol. 25: S65-S69.

• Er H, Evereklioglu C, Cumurcu T, Turkoz Y, Ozerol E, Sahin K, Doganay S 2002 Serum homocysteine level is increased and correlated with endothelin-1 and nitric oxide in Behcet's disease. Br. J. Ophthalmol. 86: 653-657. *

• Erdem H, Pay S, Musabak U, Simsek I, Dinc A, Pekel A, Sengul A 2007 Synovial angiostatic non-ELR CXC chemokines in inflammatory arthritides: does CXCL4 designate chronicity of synovitis? Rheumatol. Int. 27: 969-973. *

• Erdem H, Pay S, Serdar M, Simsek I, Dinc A, Musabak U, Pekel A, Turan M 2005 Different ELR (+) angiogenic CXC chemokine profiles in synovial fluid of patients with Behcet's disease, familial Mediterranean fever, rheumatoid arthritis, and osteoarthritis. Rheumatol. Int. 26: 162-167. *

• Ersoy O, Sivri B, Arslan S, Batman F, Bayraktar Y 2006 How much helpful is the capsule endoscopy for the diagnosis of small bowel lesions? World J. Gastroenterol. 12: 3906-3910. *

• Espinosa G, Arostegui JI, Plaza S, Rius J, Cervera R, Yague J, Font J 2005 Behcet's disease and hereditary periodic fever syndromes: casual association or causal relationship? Clin. Exp. Rheumatol. 23: S64-S66.

• Evereklioglu C 2005 Current concepts in the etiology and treatment of Behcet disease. Surv. Ophthalmol. 50: 297-350.

• Evereklioglu C 2006 Diagnostic dilemma between intestinal Behcet disease and inflammatory bowel disease with pyoderma gangrenosum. World J. Gastroenterol. 12: 5748-5751. *

• Evereklioglu C 2004 Managing the symptoms of Behcet's disease. Expert Opin. Pharmacother. 5: 317-328.

• Fadil H, Kelley RE, Gonzalez-Toledo E 2007 Differential diagnosis of multiple sclerosis. Int. Rev. Neurobiol. 79C: 393-422.

• Faulds D, Goa KL, Benfield P 1993 Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. Drugs 45: 953-1040.

• Feki M, Houman H, Ghannouchi M, Smiti-Khanfir M, Hamzaoui K, Matri LE, Mebazaa A, Kaabachi N 2004 Hyperhomocysteinaemia is associated with uveitis but not with deep venous thrombosis in Behcet's disease. Clin. Chem. Lab. Med. 42: 1417-1423.

• Felizardo M, Gomes A, Sousa M, Teixeira A, Freitas J, Tavares A, Vaz Patto J, Gomes M 2007 Immunosuppression and tuberculosis. Rev. Port. Pneumol. 13: S23-S24.

• Feng XG, Ye S, Lu Y, Xu XJ, Gu YY, Shen N, Ye P, Cheng FP, Wang AM, Chen SL 2007 Antikinectin autoantibody in Behcet's disease and several other autoimmune connective tissue diseases. Clin. Exp. Rheumatol. 25: S80-S85.

• Fernandes PF, Junior GB, Barros FA, Sousa DC, Franco LM, Patrocinio RM 2006 Behcet's disease and IgA nephropathy: report of this association in a patient from Brazil and literature review. Invest. Clin. 47: 405-411.

• Field EA, Allan RB 2003 Oral ulceration - aetiopathogenesis, clinical diagnosis and management in the gastrointestinal clinic. Aliment. Pharmacol. Ther. 18: 949-962. *

• Filik L 2008 Behcet's disease and celiac disease: is there a controversial link? Acta Gastroenterol. Belg. 71: 280.

• Florey OJ, Johns M, Esho OO, Mason JC, Haskard DO 2007 Anti-endothelial cell antibodies mediate enhanced leukocyte adhesion to cytokine-activated endothelial cells through a novel mechanism requiring cooperation between FcgammaRIIa and CXCR1/2. Blood 109: 3881-3889. *

• Fresko I, Ugurlu S, Ozbakir F, Celik A, Yurdakul S, Hamuryudan V, Yazici H 2005 Anti-Saccharomyces cerevisiae antibodies (ASCA) in Behcet's syndrome. Clin. Exp. Rheumatol. 23: S67-S70.

• Frieri M 2003 Identification of masqueraders of autoimmune disease in the office. Allergy Asthma Proc. 24: 421-429.

• Frigoul A, Lefranc MP 2005 MICA: standardized IMGT allele nomenclature, polymorphisms and diseases. Recent Res. Devel. Human Genet. 3: 95-145. *

• Gabay C 2008 Behcet's syndrome. Rev. Med. Suisse. 4: 728-730, 732-733.

• Galeazzi M, Gasbarrini G, Ghirardello A, Grandemange S, Hoffman HM, Manna R, Podswiadek M, Punzi L, Sebastiani GD, Touitou I, Doria A 2006 Autoinflammatory syndromes. Clin. Exp. Rheumatol. 24: S79-S85.

• Gallagher MJ, Quinones K, Cervantes-Castaneda RA, Yilmaz T, Foster CS 2007 Biologic response modifier therapy for refractory childhood uveitis. Br. J. Ophthalmol. 91: 1341-1344.

• Garrity JA, Coleman AW, Matteson EL, Eggenberger ER, Waitzman DM 2004 Treatment of recalcitrant idiopathic orbital inflammation (chronic orbital myositis) with infliximab. Am. J. Ophthalmol. 138: 925-930.

• Gebreselassie D, Spiegel H, Vukmanovic S 2006 Sampling of major histocompatibility complex class I-associated peptidome suggests relatively looser global association of HLA-B*5101 with peptides. Hum. Immunol. 67: 894-906.

• Gonzalez-Escribano MF, Rodriguez MR, Aguilar F, Alvarez A, Sanchez-Roman J, Nunez-Roldan A 1999 Lack of association of MICA transmembrane region polymorphism and Behcet's disease in Spain. Tissue Antigens 54: 278-281. *

• Gonzalez-Escribano MF, Rodriguez MR, Walter K, Sanchez-Roman J, Garcia-Lozano JR, Nunez-Roldan A 1998 Association of HLA-B51 subtypes and Behcet's disease in Spain. Tissue Antigens 52: 78-80.

• Goto M, Koyama H, Takahashi O, Fukui T 2007 A retrospective review of 226 hospitalized patients with fever. Intern. Med. 46: 17-22. *

• Gowri Priya C, Rathinam S, Muthukkaruppan V 2008 Evidences for endotoxin as a causative factor for leptospiral uveitis in humans. Invest. Ophthalmol. Vis. Sci. Jul 24 [Epub ahead of print].

• Granel B, Swiader L, Serratrice J, Disdier P, Weiller PJ 2000 Heat shock proteins or "stress proteins". Rev. Med. Interne. 21: 421-427.

• Greim B, Engel C, Apel A, Zettl UK 2007 Fatigue in neuroimmunological diseases. J. Neurol. 254 Suppl. 2: II102-II106.

• Guhl G, García-Diez A 2008 Subcutaneous Sweet syndrome. Dermatol. Clin. 26: 541-551.

• Gul A 2005 Behcet's disease as an autoinflammatory disorder. Curr. Drug Targets Inflamm. Allergy 4: 81-83.

• Gul A, Uyar FA, Inanc M, Ocal L, Barrett JH, Aral O, Konice M, Saruhan-Direskeneli G 2002 A weak association of HLA-B*2702 with Behcet's disease. Genes Immun. 3: 368-372. *

• Gunesacar R, Erken E, Bozkurt B, Ozer HT, Dinkci S, Erken EG, Ozbalkan Z 2007 Analysis of CD28 and CTLA-4 gene polymorphisms in Turkish patients with Behcet's disease. Int. J. Immunogenet. 34: 45-49. *

• Gupta AK, Skinner AR 2004 A review of the use of infliximab to manage cutaneous dermatoses. J. Cutan. Med. Surg. 8: 77-89. *

• Haag K, Scholmerich J 1991 Prerequisites for therapy of inflammatory bowel diseases. Pathophysiology - symptomatology - diagnosis. Fortschr. Med. 109: 232-237.

• Hamzaoui K 2007 Paradoxical high regulatory T cell activity in Behcet's disease. Clin. Exp. Rheumatol. 25: S107-S113.

• Hamzaoui K, Hamzaoui A, Guemira F, Bessioud M, Hamza M, Ayed K 2002 Cytokine profile in Behcet's disease patients. Relationship with disease activity. Scand. J. Rheumatol. 31: 205-210.

• Hamzaoui K, Hamzaoui A, Houman H 2006 CD4+CD25+ regulatory T cells in patients with Behcet's disease. Clin. Exp. Rheumatol. 24: S071-S078.

• Han SW, Kim GW, Lee J, Kim YJ, Kang YM 2005 Successful treatment with stent angioplasty for Budd-Chiari syndrome in Behcet's disease. Rheumatol. Int. 25: 234-237. *

• Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A, Houman MH, Kotter I, Olivieri I, Salvarani C, Sfikakis PP, Siva A, Stanford MR, Stubiger N, Yurdakul S, Yazici H 2008 Management of Behcet's disease: a systematic literature review for the EULAR evidence based recommendations for the management of Behcet's disease. Ann. Rheum. Dis. Apr 17 [Epub ahead of print].

• Haubrich WS 2008 Behcet of Behcet's syndrome. Gastroenterology 134: 38. *

• Heller M 2005 Behcet disease (incomplete) and cutaneous polyarteritis nosa. Dermatol. Online J. 11: 25.

• Hisaoka M, Haratake J, Nakamura T 1994 Small bile duct abnormalities and chronic intrahepatic cholestasis in Behcet's syndrome. Hepatogastroenterology 41: 267-270.

• Holman DM, Kalaaji AN 2006 Cytokines in dermatology. J. Drugs Dermatol. 5: 520-524.

• Hou S, Yang P, Du L, Zhou H, Lin X, Liu X, Kijlstra A 2008 SUMO4 gene polymorphisms in Chinese Han patients with Behcet's disease. Clin. Immunol. Jul 24 [Epub ahead of print]. *

• Houman H, Hamzaoui A, Ben Ghorbal I, Khanfir M, Feki M, Hamzaoui K 2004 Abnormal expression of chemokine receptors in Behcet's disease: relationship to intracellular Th1/Th2 cytokines and to clinical manifestations. J. Autoimmun. 23: 267-273.

• Houman MH, Neffati H, Braham A, Harzallah O, Khanfir M, Miled M, Hamzaoui K 2007 Behcet's disease in Tunisia. Demographic, clinical and genetic aspects in 260 patients. Clin. Exp. Rheumatol. 25: S58-S64.

• Howarth PH, Babu KS, Arshad HS, Lau LC, Buckley MG, McConnell W, Beckett P, Ali MA, Chauhan A, Wilson SJ, Reynolds A, Davies DE, Holgate ST 2005 Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid-dependent asthma. Thorax 60: 1012-1018. *

• Hughes EH, Collins RW, Kondeatis E, Wallace GR, Graham EM, Vaughan RW, Stanford MR 2005 Associations of major histocompatibility complex class I chain-related molecule polymorphisms with Behcet's disease in Caucasian patients. Tissue Antigens 66: 195-199. *

• Hussein A 1987 HLA-B27 associated spondyloarthritis in childhood. Monatsschr. Kinderheilkd. 135: 185-194.

• Huynh-Do U 2006 In Medea's gardens - two tales of colchicine. Ther. Umsch. 63: 783-787.

• Ida H, Kawasaki E, Miyashita T, Tanaka F, Kamachi M, Izumi Y, Huang M, Tamai M, Origuchi T, Kawakami A, Migita K, Motomura M, Yoshimura T, Eguchi K 2004 A novel mutation (T61I) in the gene encoding tumour necrosis factor receptor superfamily 1A (TNFRSF1A) in a Japanese patient with tumour necrosis factor receptor-associated periodic syndrome (TRAPS) associated with systemic lupus erythematosus. Rheumatology (Oxford) 43: 1292-1299. *

• Ilhan F, Demir T, Turkcuoglu P, Turgut B, Demir N, Godekmerdan A 2008 Th1 polarization of the immune response in uveitis in Behcet's disease. Can. J. Ophthalmol. 43: 105-108.

• Imamura Y, Kurokawa MS, Yoshikawa H, Nara K, Takada E, Masuda C, Tsukikawa S, Ozaki S, Matsuda T, Suzuki N 2005 Involvement of Th1 cells and heat shock protein 60 in the pathogenesis of intestinal Behcet's disease. Clin. Exp. Immunol. 139: 371-378. *

• Inanc N, Mumcu G, Birtas E, Elbir Y, Yavuz S, Ergun T, Fresko I, Direskeneli H 2005 Serum mannose-binding lectin levels are decreased in Behcet's disease and associated with disease severity. J. Rheumatol. 32: 287-291.

• Ishihara M, Ohno S, Mizuki N, Yamagata N, Ishida T, Naruse T, Ando A, Inoko H 1996 LMP7 polymorphism in Japanese patients with sarcoidosis and Behcet's disease. Hum. Immunol. 51: 103-105.

• Ito A, Ota M, Katsuyama Y, Inoko H, Ohno S, Mizuki N 2007 Lack of association of Toll-like receptor 9 gene polymorphism with Behcet's disease in Japanese patients. Tissue Antigens 70: 423-426. *

• Itoh Y, Inoko H, Kulski JK, Sasaki S, Meguro A, Takiyama N, Nishida T, Yuasa T, Ohno S, Mizuki N 2006 Four-digit allele genotyping of the HLA-A and HLA-B genes in Japanese patients with Behcet's disease by a PCR-SSOP-Luminex method. Tissue Antigens 67: 390-394. *

• Iwadate H, Ohira H, Saito H, Takahashi A, Rai T, Takiguchi J, Sasajima T, Kobayashi H, Watanabe H, Sato Y 2006 A case of primary biliary cirrhosis complicated by Behcet's disease and palmoplantar pustulosis. World J. Gastroenterol. 12: 2136-2138. *

• Jang WC, Nam YH, Ahn YC, Lee SH, Park SH, Choe JY, Lee SS, Kim SK 2008 Interleukin-17F gene polymorphisms in Korean patients with Behcet's disease. Rheumatol. Int. Sep 4 [Epub ahead of print]. *

• Jankowski J, Crombie I, Jankowski R 1992 Behcet's syndrome in Scotland. Postgrad. Med. J. 68: 566-570.

• Ju JH, Kwok SK, Seo SH, Yoon CH, Kim HY, Park SH 2007 Successful treatment of life-threatening intestinal ulcer in Behcet's disease with infliximab: rapid healing of Behcet's ulcer with infliximab. Clin. Rheumatol. 26: 1383-1385. *

• Kalantzis N, Papanikolaou IS, Giannakoulopoulou E, Alogari A, Kalantzis C, Papacharalampous X, Gabriel P, Alexandrakis G, Apostolopoulos P 2005 Capsule endoscopy; the cumulative experience from its use in 193 patients with suspected small bowel disease. Hepatogastroenterology 52: 414-419.

• Kalayciyan A, Orawa H, Fimmel S, Perschel FH, Gonzalez JB, Fitzner RG, Orfanos CE, Zouboulis CC 2007 Nicotine and biochanin A, but not cigarette smoke, induce anti-inflammatory effects on keratinocytes and endothelial cells in patients with Behcet's disease. J. Invest. Dermatol. 127: 81-89. *

• Kalayciyan A, Zouboulis C 2007 An update on Behcet's disease. J. Eur. Acad. Dermatol. Venereol. 21: 1-10. *

• Kalden JR 2002 Emerging role of anti-tumor necrosis factor therapy in rheumatic diseases. Arthritis Res. 4 Suppl. 2: S34-S40. *

• Kallinowski B, Noldge G, Stiehl A 1994 Crohn's disease with Behcet's syndrome like appearance: a case report. Z. Gastroenterol. 32: 642-644.

• Kamiishi T, Itoh Y, Meguro A, Nishida T, Sasaki S, Nanba K, Ohno S, Inoko H, Mizuki N 2008 Four-digit allele genotyping of HLA-A and HLA-B genes in Japanese patients with Behcet's disease (BD) by a PCR-SSOP-luminex method and stratification analysis according to each major symptom of BD. Nippon Ganka Gakkai Zasshi 112: 451-458.

• Kamoun M, Chelbi H, Houman MH, Lacheb J, Hamzaoui K 2007 Tumor necrosis factor gene polymorphisms in Tunisian patients with Behcet's disease. Hum. Immunol. 68: 201-205.

• Kanazawa N, Furukawa F 2007 Autoinflammatory syndromes with a dermatological perspective. J. Dermatol. 34: 601-618.

• Kaneko F, Oyama N, Yanagihori H, Isogai E, Yokota K, Oguma K 2008 The role of streptococcal hypersensitivity in the pathogenesis of Behcet's Disease. Eur. J. Dermatol. 18: 489-498.

• Kanski JJ 1981 Care of children with anterior uveitis. Trans. Ophthalmol. Soc. U.K. 101: 387-390.

• Kara N, Senturk N, Gunes SO, Bagci H, Yigit S, Turanli AY 2006 Lack of evidence for association between endothelial nitric oxide synthase gene polymorphism (glu298asp) with Behcet's disease in the Turkish population. Arch. Dermatol. Res. 297: 468-471. *

• Karasawa R, Ozaki S, Nishioka K, Kato T 2005 Autoantibodies to peroxiredoxin I and IV in patients with systemic autoimmune diseases. Microbiol. Immunol. 49: 57-65. *

• Karasneh J, Gul A, Ollier WE, Silman AJ, Worthington J 2005 Whole-genome screening for susceptibility genes in multicase families with Behcet's disease. Arth. Rheum. 52: 1836-1842. *

• Karasneh JA, Hajeer AH, Silman A, Worthington J, Ollier WE, Gul A 2005 Polymorphisms in the endothelial nitric oxide synthase gene are associated with Behcet's disease. Rheumatology (Oxford) 44: 614-617. *

• Kera J, Mizuki N, Ota M, Katsuyama Y, Pivetti-Pezzi P, Ohno S, Inoko H 1999 Significant associations of HLA-B*5101 and B*5108, and lack of association of class II alleles with Behcet's disease in Italian patients. Tissue Antigens 54: 565-571. *

• Kestelyn PG 2005 An eye on inflammatory eye disease. Acta Clin. Belg. 60: 270-275.

• Keystone EC 2004 The utility of tumour necrosis factor blockade in orphan diseases. Ann. Rheum. Dis. 63 Suppl. 2: ii79-ii83. *

• Kikuchi H, Aramaki K, Hirohata S 2008 Effect of infliximab in progressive neuro-Behcet's syndrome. J. Neurol. Sci. 272: 99-105.

• Kim BG, Kim YS, Kim JS, Jung HC, Song IS 2002 Diagnostic role of anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic antibodies in patients with inflammatory bowel disease. Dis. Colon Rectum 45: 1062-1069.

• Kim DH, Lee KJ, Kim YB, Lee EH, Song HJ, Kim JH, Hahm KB, Cho SW 2004 Clinical significance of erosive and/or small ulcerative lesions in the colon and terminal ileum - short-term follow-up study. Korean J. Gastroenterol. 44: 321-327.

• Kim EH, Mok JW, Bang DS, Lee ES, Lee SN, Park KS 2003 Intercellular adhesion molecule-1 polymorphisms in Korean patients with Behcet's disease. J. Korean Med. Sci. 18: 415-418. *

• Kim ES, Chung WC, Lee KM, Lee BI, Choi H, Han SW, Choi KY, Chung IS 2007 A case of intestinal Behcet's disease similar to Crohn's colitis. J. Korean Med. Sci. 22: 918-922. *

• Kim JU, Chang HK, Lee SS, Kim JW, Kim KT, Lee SW, Chung WT 2003 Endothelial nitric oxide synthase gene polymorphisms in Behcet's disease and rheumatic diseases with vasculitis. Ann. Rheum. Dis. 62: 1083-1087. *

• Kim MK, Park KS, Min JK, Cho CS, Kim HY 2005 A case of polychondritis in a patient with Behcet's disease. Korean J. Intern. Med. 20: 339-342.

• Kim SK, Jang WC, Park SB, Park DY, Bang KT, Lee SS, Jun JB, Yoo DH, Chang HK 2006 SLC11A1 gene polymorphisms in Korean patients with Behcet's disease. Scand. J. Rheumatol. 35: 398-401. *

• Kim SK, Park CK, Park YW, Jun JB, Yoo DH, Bae SC 2005 Palisaded neutrophilic granulomatous dermatitis presenting as an unusual skin manifestation in a patient with Behcet's disease. Scand. J. Rheumatol. 34: 324-327.

• Kimura T, Goto K, Yabuki K, Mizuki N, Tamiya G, Sato M, Kimura M, Inoko H, Ohno S 1998 Microsatellite polymorphism within the MICB gene among Japanese patients with Behcet's disease. Hum. Immunol. 59: 500-502.

• Kirino Y, Takeno M, Watanabe R, Murakami S, Kobayashi M, Ideguchi H, Ihata A, Ohno S, Ueda A, Mizuki N, Ishigatsubo Y 2008 Association of reduced HO-1 with excessive TLR4 expression in peripheral blood mononuclear cells of Behcet's disease. Arthritis Res. Ther. 10: R16. *

• Kitauchi S, Nishi S, Nishioka S 2000 Intestinal Behcet's disease: epidemiology, pathophysiology and potential of mesalazine. BioDrugs 13: 409-413.

• Kobashigawa T, Okamoto H, Kato J, Shindo H, Imamura T, Iizuka BE, Tanaka M, Uesato M, Ohta SJ, Terai C, Hara M, Kamatani N 2004 Ulcerative colitis followed by the development of Behcet's disease. Intern. Med. 43: 243-247. *

• Kobayashi T, Eefsen RL, Kobayashi-Sorensen C 2008 Behcet's disease. Ugeskr. Laeger. 170: 1440-1445.

• Koca SS, Akbulut H, Dag S, Artas H, Isik A 2007 Anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis and Behcet's disease. Tohoku J. Exp. Med. 213: 297-304. *

• Koksal AS, Ertugrul I, Disibeyaz S, Tola M, Kacar S, Arhan M, Aydin F, Ulker A 2005 Crohn's and Behcet's disease association presenting with superior vena cava thrombosis. Dig. Dis. Sci. 50: 1698-1701. *

• Kone-Paut I, Sanchez E, Le Quellec A, Manna R, Touitou I 2007 Autoinflammatory gene mutations in Behcet's disease. Ann. Rheum. Dis. 66: 832-834. *

• Korkmaz C, Bozan B, Kosar M, Sahin F, Gulbas Z 2002 Is there an association of plasma homocysteine levels with vascular involvement in patients with Behcet's syndrome? Clin. Exp. Rheumatol. 20: S30-S34.

• Korkmaz C, Kasifoglu T, Kebapci M 2007 Budd-Chiari syndrome in the course of Behcet's disease: clinical and laboratory analysis of four cases. Joint Bone Spine 74: 245-248.

• Kotter I, Gunaydin I, Stubiger N, Yazici H, Fresko I, Zouboulis CC, Adler Y, Steiert I, Kurz B, Wernet D, Braun B, Muller CA 2001 Comparative analysis of the association of HLA-B*51 suballeles with Behcet's disease in patients of German and Turkish origin. Tissue Antigens 58: 166-170. *

• Koubaa N, Hammami S, Nakbi A, Ben Hamda K, Mahjoub S, Kosaka T, Hammami M 2008 Relationship between thiolactonase activity and hyperhomocysteinemia according to MTHFR gene polymorphism in Tunisian Behcet's disease patients. Clin. Chem. Lab. Med. 46: 187-192. *

• Koumantaki Y, Stavropoulos C, Spyropoulou M, Messini H, Papademetropoulos M, Giziaki E, Marcomichelakis N, Palimeris G, Kaklamanis P, Kaklamani E 1998 HLA-B*5101 in Greek patients with Behcet's disease. Hum. Immunol. 59: 250-255.

• Krause I, Weinberger A 2008 Behcet's disease. Curr. Opin. Rheumatol. 20: 82-87.

• Krause L 2005 Adamantiades-Behcet's disease. Ophthalmologe 102: 329-334.

• Krause L, Kohler AK, Altenburg A, Papoutsis N, Zouboulis CC, Pleyer U, Stroux A, Foerster MH 2008 Ocular involvement is associated with HLA-B51 in Adamantiades-Behcet's disease. Eye Jun 13 [Epub ahead of print].

• Kulaber A, Tugal-Tutkun I, Yentur SP, Akman-Demir G, Kaneko F, Gul A, Saruhan-Direskeneli G 2007 Pro-inflammatory cellular immune response in Behcet's disease. Rheumatol. Int. 27: 1113-1118.

• Kunihiro K, Hata J, Haruma K, Manabe N, Tanaka S, Chayama K 2004 Sonographic detection of longitudinal ulcers in Crohn disease. Scand. J. Gastroenterol. 39: 322-326. *

• Kurien BT, Hensley K, Bachmann M, Scofield RH 2006 Oxidatively modified autoantigens in autoimmune diseases. Free Radic. Biol. Med. 41: 549-356.

• Kurien BT, Scofield RH 2008 Autoimmunity and oxidatively modified autoantigens. Autoimmun. Rev. 7: 567-573.

• Kurugoglu S, Korman U, Adaletli I, Selcuk D 2007 Enteroclysis in older children and teenagers. Pediatr. Radiol. 37: 457-466. *

• Lapadula G 2005 Biologic therapy with anti-TNFalpha in spondyloarthritides and other autoimmune diseases. Reumatismo 57: S22-S29.

• Larner AJ 2007 Neurological signs: Behcet's disease, coeliac disease, both, or neither? Eur. J. Neurol. 14: e6.

• Le Jeune S, Pistorius MA, Planchon B, Pottier P 2008 Risk of venous thromboembolism in acute medical illnesses. Part 2: Situations at risk in ambulatory, hospital and internal medicine settings. Rev. Med. Interne. 29: 462-475.

• Lee CK, Kim HJ 2007 Pathogenesis and treatment of intestinal Behcet's disease. Korean J. Gastroenterol. 50: 3-8.

• Lee CR, Kim WH, Cho YS, Kim MH, Kim JH, Park IS, Bang D 2001 Colonoscopic findings in intestinal Behcet's disease. Inflamm. Bowel Dis. 7: 243-249. *

• Lee EB, Kim JY, Lee YJ, Park MH, Song YW 2003 TNF and TNF receptor polymorphisms in Korean Behcet's disease patients. Hum. Immunol. 64: 614-620.

• Lee EB, Kim JY, Zhao J, Park MH, Song YW 2007 Haplotype association of IL-8 gene with Behcet's disease. Tissue Antigens 69: 128-132. *

• Lee GH, Kim CG, Kim JS, Jung HC, Song IS 2005 Frequency analysis of NOD2 gene mutations in Korean patients with Crohn's disease. Korean J. Gastroenterol. 45: 162-168.

• Lee JJ, Beebout S, Lee AG, Tuetken R, Weinberg DA 2005 Blood-tinged stools and blood-shot eyes. Surv. Ophthalmol. 50: 476-484.

• Lee MT, Hooper LC, Kump L, Hayashi K, Nussenblatt R, Hooks JJ, Detrick B 2007 Interferon-beta and adhesion molecules (E-selectin and s-intracellular adhesion molecule-1) are detected in sera from patients with retinal vasculitis and are induced in retinal vascular endothelial cells by Toll-like receptor 3 signalling. Clin. Exp. Immunol. 147: 71-80. *

• Lee SH, Kim SD, Kim SH, Kim HR, Oh EJ, Yoon CH, Lee SH, Kim HY, Park SH 2005 EBV-associated haemophagocytic syndrome in a patient with Behcet's disease. Scand. J. Rheumatol. 34: 320-323.

• Leistner K, Wessel G 1982 Epidemiologic aspects of seronegative spondylarthritis. Z. Gesamte. Inn. Med. 37: 627-632.

• Letsinger JA, McCarty MA, Jorizzo JL 2005 Complex aphthosis: a large case series with evaluation algorithm and therapeutic ladder from topicals to thalidomide. J. Am. Acad. Dermatol. 52: 500-508.

• Lew W, Chang JY, Jung JY, Bang D 2008 Increased expression of interleukin-23 p19 mRNA in erythema nodosum-like lesions of Behcet's disease. Br. J. Dermatol. 158: 505-511. *

• Lidar M, Kedem R, Mor A, Levartovsky D, Langevitz P, Livneh A 2005 Arthritis as the sole episodic manifestation of familial Mediterranean fever. J. Rheumatol. 32: 859-862.

• Lipozencic J, Ljubojevic S 2004 Langerhans' cells in dermatology. Arh Hig Rada Toksikol 55: 167-174.

• Liu JX, Wang HH 2008 Clinical and pathological features of benign ileocecal ulcerative lesions discovered by ileocolonoscopy: analysis of 31 cases. Zhonghua Yi Xue Za Zhi 88: 823-825.

• Lotti TM, Comacchi C, Ghersetich I 1999 Cutaneous necrotizing vasculitis. Relation to systemic disease. Adv. Exp. Med. Biol. 455: 115-125.

• Lu Y, Ye P, Chen SL, Tan EM, Chan EK 2005 Identification of kinectin as a novel Behcet's disease autoantigen. Arthritis Res. Ther. 7: R1133-R1139. *

• Maca SM, Scharitzer M, Barisani-Asenbauer T 2006 Uveitis and neurologic diseases: an often overlooked relationship. Wien. Klin. Wochenschr. 118: 273-279. *

• Mahesh SP, Li Z, Buggage R, Mor F, Cohen IR, Chew EY, Nussenblatt RB 2005 Alpha tropomyosin as a self-antigen in patients with Behcet's disease. Clin. Exp. Immunol. 140: 368-375. *

• Mao L, Dong H, Yang P, Zhou H, Huang X, Lin X, Kijlstra A 2008 MALDI-TOF/TOF-MS reveals elevated serum haptoglobin and amyloid A in Behcet's disease. J. Proteome Res. Aug 29 [Epub ahead of print]. *

• Margutti P, Matarrese P, Conti F, Colasanti T, Delunardo F, Capozzi A, Garofalo T, Profumo E, Rigano R, Siracusano A, Alessandri C, Salvati B, Valesini G, Malorni W, Sorice M, Ortona E 2008 Autoantibodies to the C-terminal subunit of RLIP76 induce oxidative stress and endothelial cell apoptosis in immune-mediated vascular diseases and atherosclerosis. Blood 111: 4559-4570. *

• Marshall SE 2004 Behcet's disease. Best Pract. Res. Clin. Rheumatol. 18: 291-311.

• Maruotti N, Cantatore FP, Ribatti D 2006 Thalidomide in treatment of connective diseases and vasculities. Reumatismo 58: 187-190.

• Matsui T, Kurokawa M, Kobata T, Oki S, Azuma M, Tohma S, Inoue T, Yamamoto K, Nishioka K, Kato T 1999 Autoantibodies to T cell costimulatory molecules in systemic autoimmune diseases. J. Immunol. 162: 4328-4335. *

• Matsui T, Otsuka M, Maenaka K, Furukawa H, Yabe T, Yamamoto K, Nishioka K, Kato T 2001 Detection of autoantibodies to killer immunoglobulin-like receptors using recombinant fusion proteins for two killer immunoglobulin-like receptors in patients with systemic autoimmune diseases. Arthritis Rheum. 44: 384-388. *

• Mayo I, Arribas J, Villoslada P, Alvarez DoForno R, Rodriguez-Vilarino S, Montalban X, De Sagarra MR, Castano JG 2002 The proteasome is a major autoantigen in multiple sclerosis. Brain 125: 2658-2667. *

• Melikoglu M, Fresko I, Mat C, Ozyazgan Y, Gogus F, Yurdakul S, Hamuryudan V, Yazici H 2005 Short-term trial of etanercept in Behcet's disease: a double blind, placebo controlled study. J. Rheumatol. 32: 98-105.

• Middleton D, Meenagh A, Sleator C, Gourraud PA, Ayna T, Tozkir H, Köse AA, Azizleri G, Diler AS 2007 No association of KIR genes with Behcet's disease. Tissue Antigens 70: 435-438. *

• Mihara S, Suzuki N 2007 Role of Txk, a member of the Tec family of tyrosine kinases, in immune-inflammatory diseases. Int. Rev. Immunol. 26: 333-348.

• Mizuki N, Inoko H, Ando H, Nakamura S, Kashiwase K, Akaza T, Fujino Y, Masuda K, Takiguchi M, Ohno S 1993 Behcet's disease associated with one of the HLA-B51 subantigens, HLA-B* 5101. Am. J. Ophthalmol. 116: 406-409.

• Mizuki N, Inoko H, Mizuki N, Tanaka H, Kera J, Tsuiji K, Ohno S 1992 Human leukocyte antigen serologic and DNA typing of Behcet's disease and its primary association with B51. Invest. Ophthalmol. Vis. Sci. 33: 3332-3340. *

• Mizuki N, Inoko H, Ohno S 1997 Pathogenic gene responsible for the predisposition of Behcet's disease. Int. Rev. Immunol. 14: 33-48.

• Mizuki N, Inoko H, Ohno S 1997 Molecular genetics (HLA) of Behcet's disease. Yonsei Med. J. 38: 333-349. *

• Mizuki N, Inoko H, Sugimura K, Nishimura K, Nakamura S, Tanaka H, Mizuki N, Mizuki H, Inaba G, Tsuji K, et al 1992 RFLP analysis in the TNF-beta gene and the susceptibility to alloreactive NK cells in Behcet's disease. Invest. Ophthalmol. Vis. Sci. 33: 3084-3090. *

• Mizuki N, Meguro A, Tohnai I, Gul A, Ohno S, Mizuki N 2007 Association of major histocompatibility complex class I chain-related gene A and HLA-B alleles with Behcet's disease in Turkey. Jpn. J. Ophthalmol. 51: 431-4361.

• Mizuki N, Ohno S 1996 Immunogenetic studies of Behcet's disease. Rev. Rhum. Engl. Ed. 63: 520-527.

• Mizuki N, Ohno S, Ando H, Chen L, Palimeris GD, Stavropoulos-Ghiokas E, Ishihara M, Goto K, Nakamura S, Shindo Y, Isobe K, Ito N, Inoko H 1997 A strong association between HLA-B*5101 and Behcet's disease in Greek patients. Tissue Antigens 50: 57-60.

• Mizuki N, Ohno S, Ando H, Kimura M, Ishihara M, Miyata S, Nakamura S, Mizuki N, Inoko H 1996 HLA-C genotyping of patient with Behcet's disease in the Japanese population. Hum. Immunol. 50: 47-53.

• Mizuki N, Ohno S, Sato T, Ishihara M, Miyata S, Nakamura S, Naruse T, Mizuki H, Tsuji K, Inoko H 1995 Microsatellite polymorphism between the tumor necrosis factor and HLA-B genes in Behcet's disease. Hum. Immunol. 43: 129-135.

• Mizuki N, Ohno S, Tanaka H, Sugimura K, Seki T, Mizuki N, Kera J, Inaba G, Tsuji K, Inoko H 1992 Association of HLA-B51 and lack of association of class II alleles with Behcet's disease. Tissue Antigens 40: 22-30.

• Mizuki N, Ota M, Katsuyama Y, Yabuki K, Ando H, Goto K, Nakamura S, Bahram S, Ohno S, Inoko H 1999 Association analysis between the MIC-A and HLA-B alleles in Japanese patients with Behcet's disease. Arthritis Rheum. 42: 1961-1966. *

• Mizuki N, Ota M, Katsuyama Y, Yabuki K, Ando H, Shiina T, Nomura E, Onari K, Ohno S, Inoko H 2001 HLA-B*51 allele analysis by the PCR-SBT method and a strong association of HLA-B*5101 with Japanese patients with Behcet's disease. Tissue Antigens 58: 181-184. *

• Mizuki N, Ota M, Katsuyama Y, Yabuki K, Ando H, Shiina T, Palimeris GD, Kaklamani E, Ito D, Ohno S, Inoko H 2002 Sequencing-based typing of HLA-B*51 alleles and the significant association of HLA-B*5101 and -B*5108 with Behcet's disease in Greek patients. Tissue Antigens 59: 118-121. *

• Mizuki N, Ota M, Katsuyama Y, Yabuki K, Ando H, Yoshida M, Onari K, Nikbin B, Davatchi F, Chams H, Ghaderi AA, Ohno S, Inoko H 2001 HLA class I genotyping including HLA-B*51 allele typing in the Iranian patients with Behcet's disease. Tissue Antigens 57: 457-462. *

• Mizuki N, Ota M, Kimura M, Ohno S, Ando H, Katsuyama Y, Yamazaki M, Watanabe K, Goto K, Nakamura S, Bahram S, Inoko H 1997 Triplet repeat polymorphism in the transmembrane region of the MICA gene: a strong association of six GCT repetitions with Behcet disease. Proc. Natl. Acad. Sci. U.S.A. 94: 1298-1303. *

• Mizuki N, Ota M, Yabuki K, Katsuyama Y, Ando H, Palimeris GD, Kaklamani E, Accorinti M, Pivetti-Pezzi P, Ohno S, Inoko H 2000 Localization of the pathogenic gene of Behcet's disease by microsatellite analysis of three different populations. Invest. Ophthalmol. Vis. Sci. 41: 3702-3708. *

• Mizuki N, Yabuki K, Ota M, Verity D, Katsuyama Y, Ando H, Onari K, Goto K, Imagawa Y, Mandanat W, Fayyad F, Stanford M, Ohno S, Inoko H 2001 Microsatellite mapping of a susceptible locus within the HLA region for Behcet's disease using Jordanian patients. Hum. Immunol. 62: 186-190.

• Moll JM, Haslock I, Macrae IF, Wright V 1974 Associations between ankylosing spondylitis, psoriatic arthritis, Reiter's disease, the intestinal arthropathies, and Behcet's syndrome. Medicine (Baltimore) 53: 343-364.

• Mor F, Weinberger A, Cohen IR 2002 Identification of alpha-tropomyosin as a target self-antigen in Behcet's syndrome. Eur. J. Immunol. 32: 356-365. *

• Mumcu G, Inanc N, Yavuz S, Direskeneli H 2007 The role of infectious agents in the pathogenesis, clinical manifestations and treatment strategies in Behcet's disease. Clin. Exp. Rheumatol. 25: S27-S33.

• Munoz-Saa I, Cambra A, Pallares L, Espinosa G, Juan A, Pujalte F, Matamoros N, Mila J, Julia MR 2006 Allelic diversity and affinity variants of MICA are imbalanced in Spanish patients with Behcet's disease. Scand. J. Immunol. 64: 77-82. *

• Nakamura T, Yagi H, Kurachi K, Suzuki S, Konno H 2006 Intestinal Behcet's disease with pyoderma gangrenosum: a case report. World J. Gastroenterol. 12: 979-981. *

• Nakao K, Isashiki Y, Sonoda S, Uchino E, Shimonagano Y, Sakamoto T 2007 Nitric oxide synthase and superoxide dismutase gene polymorphisms in Behcet disease. Arch. Ophthalmol. 125: 246-251. *

• Nara K, Kurokawa MS, Chiba S, Yoshikawa H, Tsukikawa S, Matsuda T, Suzuki N 2008 Involvement of innate immunity in the pathogenesis of intestinal Behcet's disease. Clin. Exp. Immunol. 152: 245-251. *

• Nishiyama M, Takahashi M, Manaka K, Suzuki S, Saito M, Nakae K 2005 Clinical features of Japanese patients with Behcet's disease and MICA polymorphism. Jpn. J. Ophthalmol. 49: 424-426.

• Nishiyama M, Takahashi M, Manaka KI, Suzuki S, Saito M, Nakae K 2006 Microsatellite polymorphisms of the MICA gene among Japanese patients with Behcet's disease. Can. J. Ophthalmol. 41: 210-215. *

• Nkam I, Cottereau MJ 2006 Acute psychosis and Behcet's disease: a case report. Encephale. 32: 385-388.

• No authors listed 2008 Behcet's disease. Vestn. Ross. Akad. Med. Nauk. 6: 33-37.

• Nomura E, Sato M, Suemizu H, Watanabe T, Kimura T, Yabuki K, Goto K, Ito N, Bahram S, Inoko H, Mizuki N, Ohno S, Kimura M 2003 Hyperkeratosis and leukocytosis in transgenic mice carrying MHC class I chain-related gene B (MICB). Tissue Antigens 61: 300-307. *

• Ohta A, Nagai M, Nishina M, Shibazaki S, Ishijima H, Izumida M 2007 Age at the onset of intractable disease: based on a clinical database for patients receiving financial aid for treatment. Nippon Koshu Eisei Zasshi 54: 3-14.

• Okka M, Ozturk M, Kockar MC, Bavbek N, Rasier Y, Gunduz K 2002 Plasma homocysteine level and uveitis in Behcet's disease. Isr. Med. Assoc. J. 4: S931-S934.

• Oksel F, Keser G, Ozmen M, Aksu K, Kitapcioglu G, Berdeli A, Doganavsargil E 2006 Endothelial nitric oxide synthase gene Glu298Asp polymorphism is associated with Behcet's disease. Clin. Exp. Rheumatol. 24: S079-S082.

• Okudan N, Acar H, Gokbel H, Mevlitoglu I, Sari F 2006 Evaluation of leptin level and Ob gene polymorphism in patients with Behcet's disease. Arch. Dermatol. Res. 298: 127-130. *

• Okunuki Y, Usui Y, Kezuka T, Hattori T, Masuko K, Nakamura H, Yudoh K, Goto H, Usui M, Nishioka K, Kato T, Takeuchi M 2008 Proteomic surveillance of retinal autoantigens in endogenous uveitis: implication of esterase D and brain-type creatine kinase as novel autoantigens. Mol. Vis. 14: 1094-1104.

• Oshitani N, Hato F, Kitagawa S, Watanabe K, Fujiwara Y, Higuchi K, Matsumoto T, Arakawa T 2003 Distinct elevation of levels of anti-Caenorhabditis elegans antibody in sera of patients with inflammatory bowel disease. Clin. Diagn. Lab. Immunol. 10: 856-861. *

• Ozen S 1999 Vasculopathy, Behcet's syndrome, and familial Mediterranean fever. Curr. Opin. Rheumatol. 11: 393-398.

• Ozkul Y, Evereklioglu C, Borlu M, Taheri S, Calis M, Dundar M, Ilhan O 2005 5,10-Methylenetetrahydrofolate reductase C677T gene polymorphism in Behcet's patients with or without ocular involvement. Br. J. Ophthalmol. 89: 1634-1637. *

• Oztas MO, Onder M, Gurer MA, Bukan N, Sancak B 2005 Serum interleukin 18 and tumour necrosis factor-alpha levels are increased in Behcet's disease. Clin. Exp. Dermatol. 30: 61-63. *

• Oztas P, Lortlar N, Polat M, Alli N, Omeroglu S, Basman A 2007 Caspase-9 expression is increased in endothelial cells of active Behcet's disease patients. Int. J. Dermatol. 46: 172-176. *

• Pacheco PA, Taylor SR, Cuchacovich MT, Diaz GV 2008 Azathioprine in the management of autoimmune uveitis. Ocul. Immunol. Inflamm. 16: 161-165.

• Padula A, Ciancio G, Cantini F, Barozzi L, Scarano E, Niccoli L, Olivieri I 1999 Coexisting Behcet's syndrome and spondyloarthritis. Clin. Rheumatol. 18: 499-500. *

• Papadimitraki ED, Kyrmizakis DE, Kritikos I, Boumpas DT 2004 Ear-nose-throat manifestations of autoimmune rheumatic diseases. Clin. Exp. Rheumatol. 22: 485-494.

• Park KS, Min K, Nam JH, Bang D, Lee ES, Lee S 2005 Association of HYPA haplotype in the mannose-binding lectin gene-2 with Behcet's disease. Tissue Antigens 65: 260-265. *

• Park KS, Park JS, Nam JH, Bang D, Sohn S, Lee ES 2007 HLA-E*0101 and HLA-G*010101 reduce the risk of Behcet's disease. Tissue Antigens 69: 139-144. *

• Park SH, Park KS, Seo YI, Min DJ, Kim WU, Kim TG, Cho CS, Mok JW, Park KS, Kim HY 2002 Association of MICA polymorphism with HLA-B51 and disease severity in Korean patients with Behcet's disease. J. Korean Med. Sci. 17: 366-370. *

• Park YW, Park JJ, Lee JB, Lee SS 2007 Development of Henoch-Schonlein purpura in a patient with Behcet's disease presenting with recurrent deep vein thrombosis. Clin. Exp. Rheumatol. 25: S96-S98.

• Paul M, Klein T, Krause I, Molad Y, Narinsky R, Weinberger A 2001 Allelic distribution of HLA-B*5 in HLA-B5-positive Israeli patients with Behcet's disease. Tissue Antigens 58: 185-186. *

• Pay S, Abbasov T, Erdem H, Musabak U, Simsek I, Pekel A, Akdogan A, Sengul A, Dinc A 2007 Serum MMP-2 and MMP-9 in patients with Behcet's disease: do their higher levels correlate to vasculo-Behcet's disease associated with aneurysm formation? Clin. Exp. Rheumatol. 25: S70-S75.

• Pay S, Erdem H, Pekel A, Simsek I, Musabak U, Sengul A, Dinc A 2006 Synovial proinflammatory cytokines and their correlation with matrix metalloproteinase-3 expression in Behcet's disease. Does interleukin-1beta play a major role in Behcet's synovitis? Rheumatol. Int. 26: 608-613. *

• Pay S, Musabak U, Simsek I, Pekel A, Erdem H, Dinc A, Sengul A 2006 Expression of CXCR-1 and CXCR-2 chemokine receptors on synovial neutrophils in inflammatory arthritides: does persistent or increasing expression of CXCR-2 contribute to the chronic inflammation or erosive changes? Joint Bone Spine 73: 691-696.

• Pay S, Simsek I, Erdem H, Dinc A 2007 Immunopathogenesis of Behcet's disease with special emphasize on the possible role of antigen presenting cells. Rheumatol. Int. 27: 417-424. *

• Pay S, Simsek I, Erdem H, Pekel A, Musabak U, Sengul A, Dinc A 2007 Dendritic cell subsets and type I interferon system in Behcet's disease: does functional abnormality in plasmacytoid dendritic cells contribute to Th1 polarization? Clin. Exp. Rheumatol. 25: S34-S40.

• Perri AJ 3rd, Hsu S 2003 A review of thalidomide's history and current dermatological applications. Dermatol. Online J. 9: 5.

• Philipper M, Schumacher B, Donner A, Neuhaus H 2004 Behcet's disease with gastrointestinal involvement without evidence for a chronic inflammatory bowel disease. Z. Gastroenterol. 42: 743-747.

• Picco P, Porfirio B, Gattorno M, Buoncompagni A, Falcini F, Cusano R, Bordo D, Pistoia V, Ravazzolo R, Seri M 2002 MICA gene polymorphisms in an Italian paediatric series of juvenile Behcet disease. Int. J. Mol. Med. 10: 575-578.

• Pincus T, Sokka T 2007 Can a Multi-Dimensional Health Assessment Questionnaire (MDHAQ) and Routine Assessment of Patient Index Data (RAPID) scores be informative in patients with all rheumatic diseases? Best Pract. Res. Clin. Rheumatol. 21: 733-753.

• Plskova J, Greiner K, Muckersie E, Duncan L, Forrester JV 2006 Interferon-alpha: a key factor in autoimmune disease? Invest. Ophthalmol. Vis. Sci. 47: 3946-3950. *

• Porzionato A, Alaggio R, Aprile A 2005 Perianal and vulvar Crohn's disease presenting as suspected abuse. Forensic Sci. Int. 155: 24-27.

• Pras E, Neumann R, Zandman-Goddard G, Levy Y, Assia EI, Shoenfeld Y, Langevitz P 2004 Intraocular inflammation in autoimmune diseases. Semin. Arthritis Rheum. 34: 602-609. *

• Quintana FJ, Cohen IR 2004 The natural autoantibody repertoire and autoimmune disease. Biomed. Pharmacother. 58: 276-281.

• Raedler A, Bredow G, Kirch W, Thiele HG, Greten H 1986 In vivo activated peripheral T cells in autoimmune disease. J. Clin. Lab. Immunol. 19: 181-186.

• Rashtak S, Pittelkow MR 2008 Skin involvement in systemic autoimmune diseases. Curr. Dir. Autoimmun. 10: 344-358.

• Reimold AM 2002 TNFalpha as therapeutic target: new drugs, more applications. Curr. Drug Targets Inflamm. Allergy 1: 377-392.

• Reske D, Petereit HF 2004 Cerebrospinal fluid and immunological parameters for differentiation of chronic inflammatory central nervous system disease. Nervenarzt 75: 945-952.

• Reske D, Petereit HF, Heiss WD 2005 Difficulties in the differentiation of chronic inflammatory diseases of the central nervous system - value of cerebrospinal fluid analysis and immunological abnormalities in the diagnosis. Acta Neurol. Scand. 112: 207-213. *

• Rhodes JM, Collins P 2005 Lessons for inflammatory bowel disease from rheumatology. Dig. Liver Dis. 38: 157-162.

• Ricart JM, Ramon LA, Vaya A, Espana F, Santaolaria ML, Todoli J, Castello R, Fontcuberta J, Estelles A 2008 Fibrinolytic inhibitor levels and polymorphisms in Behcet disease and their association with thrombosis. Br. J. Haematol. 141: 716-719.

• Rozenbaum M, Boulman N, Slobodin G, Zisman D, Mader R, Yankevitch A, Weinberger A, Rosner I 2007 Behcet disease in adult Druzes in North Israel: the influence of ethnic origin on disease expression and severity. J. Clin. Rheumatol. 13: 124-127.

• Saadat M 2006 Association between K469E polymorphism of intracellular adhesion molecules-1 ICAM-1 and Behcet's disease. Saudi Med. J. 27: 1934.

• Sadreddini S, Noshad H, Molaeefard M, Noshad R 2008 Treatment of retinal vasculitis in Behcet's disease with rituximab. Mod. Rheumatol. 18: 306-308.

• Sahin N, Bicakcigil M, Atagunduz P, Direskeneli H, Saruhan-Direskeneli G 2007 PTPN22 gene polymorphism in Behcet's disease. Tissue Antigens 70: 432-434. *

• Saibeni S, Bottasso B, Spina L, Bajetta M, Danese S, Gasbarrini A, De Franchis R, Vecchi M 2004 Assessment of thrombin-activatable fibrinolysis inhibitor (TAFI) plasma levels in inflammatory bowel diseases. Am. J. Gastroenterol. 99: 1966-1970. *

• Sakane T, Miura K 1996 Research for basic and clinical aspects of Behcet's disease - recent advance and future. Nippon Rinsho 54: 870-884.

• Sallakci N, Bacanli A, Coskun M, Yavuzer U, Alpsoy E, Yegin O 2005 CTLA-4 gene 49A/G polymorphism in Turkish patients with Behcet's disease. Clin. Exp. Dermatol. 30: 546-550.

• Salvarani C, Boiardi L, Mantovani V, Olivieri I, Ciancio G, Cantini F, Salvi F, Malatesta R, Molinotti C, Govoni M, Trotta F, Filippini D, Paolazzi G, Viggiani M 2001 Association of MICA alleles and HLA-B51 in Italian patients with Behcet's disease. J. Rheumatol. 28: 1867-1870.

• San Luis Miranda R, Lazaro Castillo JL, Enciso Gomez R, Arias Monroy LG, Ramirez Reyes HA, Leon Avila JL, Munayer Calderon J 2007 Right ventricular thrombous and pulmonary artery aneurysms in Behcet's disease. Report of one case. Arch. Cardiol. Mex. 77: 130-136.

• Sari I, Birlik M, Gonen C, Akar S, Gurel D, Onen F, Akkoc N 2008 Cytomegalovirus colitis in a patient with Behcet's disease receiving tumor necrosis factor alpha inhibitory treatment. World J. Gastroenterol. 14: 2912-2914. *

• Saruhan-Direskeneli G, Uyar FA, Cefle A, Onder SC, Eksioglu-Demiralp E, Kamali S, Inanc M, Ocal L, Gul A 2004 Expression of KIR and C-type lectin receptors in Behcet's disease. Rheumatology (Oxford) 43: 423-427. *

• Saruhan-Direskeneli G, Yentur SP, Akman-Demir G, Isik N, Serdaroglu P 2003 Cytokines and chemokines in neuro-Behcet's disease compared to multiple sclerosis and other neurological diseases. J. Neuroimmunol. 145: 127-134.

• Sarwar H, McGrath H Jr, Espinoza LR 2005 Successful treatment of long-standing neuro-Behcet's disease with infliximab. J. Rheumatol. 32: 181-183.

• Sayarlioglu M, Cinal A, Topcu N, Demirok A 2004 Effect of infliximab on refractory uveitis in Behcet's disease. Ann. Pharmacother. 38: 901-902.

• Schaerli P, Britschgi M, Keller M, Steiner UC, Steinmann LS, Moser B, Pichler WJ 2004 Characterization of human T cells that regulate neutrophilic skin inflammation. J. Immunol. 173: 2151-2158. *

• Scharf Y, Zonis S 1980 Histocompatibility antigens (HLA) and uveitis. Surv. Ophthalmol. 24: 220-228.

• Schofield P 2005 Dementia associated with toxic causes and autoimmune disease. Int. Psychogeriatr. 17 Suppl. 1: S129-S147.

• Seo J, Park JS, Nam JH, Bang D, Sohn S, Lee ES, Park KS 2007 Association of CD94/NKG2A, CD94/NKG2C, and its ligand HLA-E polymorphisms with Behcet's disease. Tissue Antigens 70: 307-313. *

• Sfikakis PP, Iliopoulos A, Elezoglou A, Kittas C, Stratigos A 2005 Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheum. 52: 2513-2518. *

• Soto-Vega E, Garcia-Munoz R, Richaud-Patin Y, Zuniga-Ramos J, Crispin JC, Diaz-Jouanen E, Flores-Suarez LF, Llorente L, Granados J 2004 Class I and class II MHC polymorphisms in Mexican patients with Behcet's disease. Immunol. Lett. 93: 211-215.

• Srivastava N, Chand S, Bansal M, Srivastava K, Singh S 2007 Familial Behcet's disease. Indian J. Dermatol. Venereol. Leprol. 73: 260-261. *

• Statkute L, Oyama Y, Barr WG, Sufit R, Ho S, Verda L, Loh Y, Yaung K, Quigley K, Burt RK 2008 Autologous non-myeloablative hematopoietic stem cell transplantation for refractory systemic vasculitis. Ann. Rheum. Dis. 67: 991-997.

• Stojanov S, McDermott MF 2005 The tumour necrosis factor receptor-associated periodic syndrome: current concepts. Expert Rev. Mol. Med. 7: 1-18.

• Stokes DG, Kremer JM 2003 Potential of tumor necrosis factor neutralization strategies in rheumatologic disorders other than rheumatoid arthritis. Semin. Arthritis Rheum. 33: 1-18. *

• Suzuki Kurokawa M, Suzuki N 2004 Behcet's disease. Clin. Exp. Med. 4: 10-20.

• Tada Y, Koarada S, Haruta Y, Mitamura M, Ohta A, Nagasawa K 2006 The association of Behcet's disease with myelodysplastic syndrome in Japan: a review of the literature. Clin. Exp. Rheumatol. 24: S115-S119.

• Takahashi H, Ohara M, Imai K 2004 Collagen diseases with gastrointestinal manifestations. Nihon Rinsho Meneki Gakkai Kaishi 27: 145-155.

• Takechi U, Okada K, Uozumi T, Tsuji S 2008 Longitudinally extensive spinal cord lesion in a case of neuro-Behcet disease. Rinsho Shinkeigaku 48: 48-51.

• Takemoto Y, Naruse T, Namba K, Kitaichi N, Ota M, Shindo Y, Mizuki N, Gul A, Madanat W, Chams H, Davatchi F, Inoko H, Ohno S, Kimura A 2008 Re-evaluation of heterogeneity in HLA-B*510101 associated with Behcet's disease. Tissue Antigens Aug 12 [Epub ahead of print]. *

• Takeno M, Ishigatsubo Y 2004 Behcet's disease and inflammatory bowel disease. Intern. Med. 43: 172-173. *

• Takizawa K, Takeuchi F, Nabeta H, Hirohata S, Takeuchi A, Matsumura Y, Yamamoto K 2003 Association of transporter associated with antigen processing genes with Behcet's disease in Japanese. Autoimmunity 36: 161-165.

• Tamer L, Tursen U, Eskandari G, Ates NA, Ercan B, Yildirim H, Atik U 2005 N-acetyltransferase 2 polymorphisms in patients with Behcet's disease. Clin. Exp. Dermatol. 30: 56-60. *

• Tamiya G, Ota M, Katsuyama Y, Shiina T, Oka A, Makino S, Kimura M, Inoko H 1998 Twenty-six new polymorphic microsatellite markers around the HLA-B, -C and -E loci in the human MHC class I region. Tissue Antigens 51: 337-346.

• Tamiya G, Shiina T, Oka A, Tomizawa M, Ota M, Katsuyama Y, Yoshitome M, Makino S, Kimura M, Inoko H 1999 New polymorphic microsatellite markers in the human MHC class I region. Tissue Antigens 54: 221-228.

• Tantisirin O, Puavilai S 2003 Long-term follow-up of erythema nodosum. J. Med. Assoc. Thai. 86: 1095-1100.

• Tasli L, Mat C, De Simone C, Yazici H 2006 Lactobacilli lozenges in the management of oral ulcers of Behcet's syndrome. Clin. Exp. Rheumatol. 24: S083-S086.

• Taysi S, Sari RA, Dursun H, Yilmaz A, Keles M, Cayir K, Akyuz M, Uyanik A, Guvenc A 2008 Evaluation of nitric oxide synthase activity, nitric oxide, and homocysteine levels in patients with active Behcet's disease. Clin. Rheumatol. Jul 18 [Epub ahead of print].

• Tellier Z 2005 Intravenous immunoglobulin in eye involvement. Clin. Rev. Allergy Immunol. 29: 295-306.

• Theodoridou A, Settas L 2006 Demyelination in rheumatic diseases. J. Neurol. Neurosurg. Psychiatry 77: 290-295.

• Theodoridou A, Settas L 2008 Demyelination in rheumatic diseases. Postgrad. Med. J. 84: 127-132.

• Theodossiadis PG, Markomichelakis NN, Sfikakis PP 2007 Tumor necrosis factor antagonists: preliminary evidence for an emerging approach in the treatment of ocular iInflammation. Retina 27: 399-413.

• Thirion L, Picard D, Mejjad O, Courville P, Le Loet X, Joly P 2006 Necrotic ulcerations of cutaneous vasculitis in rheumatoid arthritis: treatment with anti-TNFalpha. Ann. Dermatol. Venereol. 133: 453-455.

• Tognon S, Graziani G, Marcolongo R 2007 Anti-TNF-alpha therapy in seven patients with Behcet's uveitis: advantages and controversial aspects. Ann. N. Y. Acad. Sci. 1110: 474-484.

• Tran TH, Milea D, Cassoux N, Bodaghi B, Bourgeois P, Lehoang P 2005 Optic neuritis associated with infliximab. J. Fr. Ophtalmol. 28: 201-204.

• Travis SP, Czajkowski M, McGovern DP, Watson RG, Bell AL 2001 Treatment of intestinal Behcet's syndrome with chimeric tumour necrosis factor alpha antibody. Gut 49: 725-728. *

• Trent JT, Kerdel FA 2005 Tumor necrosis factor alpha inhibitors for the treatment of dermatologic diseases. Dermatol. Nurs. 17: 97-107.

• Treusch M, Vonthein R, Baur M, Gunaydin I, Koch S, Stubiger N, Eckstein AK, Peter HH, Ness T, Zierhut M, Kotter I 2004 Influence of human recombinant interferon-alpha2a (rhIFN-alpha2a) on altered lymphocyte subpopulations and monocytes in Behcet's disease. Rheumatology (Oxford) 43: 1275-1282. *

• Triolo G, Accardo-Palumbo A, Dieli F, Ciccia F, Ferrante A, Giardina E, Licata G 2002 Humoral and cell mediated immune response to cow's milk proteins in Behcet's disease. Ann. Rheum. Dis. 61: 459-462. *

• Tsantes AE, Nikolopoulos GK, Bagos PG, Rapti E, Mantzios G, Kapsimali V, Travlou A 2007 Association between the plasminogen activator inhibitor-1 4G/5G polymorphism and venous thrombosis. A meta-analysis. Thromb. Haemost. 97: 907-913.

• Turan B, Pfister K, Diener PA, Hell M, Moller B, Boyvat A, Ergin S, Villiger PM 2008 Soluble tumour necrosis factor receptors sTNFR1 and sTNFR2 are produced at sites of inflammation and are markers of arthritis activity in Behcet's disease. Scand. J. Rheumatol. 37: 135-141.

• Turgut S, Turgut G, Atalay EO, Atalay A 2005 Angiotensin-converting enzyme I/D polymorphism in Behcet's disease. Med. Princ. Pract. 14: 213-216.

• Turkcapar N, Tuncali T, Kutlay S, Burhan BY, Kinikli G, Erturk S, Duman M 2007 The contribution of genotypes at the MICA gene triplet repeat polymorphisms and MEFV mutations to amyloidosis and course of the disease in the patients with familial Mediterranean fever. Rheumatol. Int. 27: 545-551. *

• Tutuncu Z, Morgan GJ Jr, Kavanaugh A 2002 Anti-TNF therapy for other inflammatory conditions. Clin. Exp. Rheumatol. 20 (6 Suppl. 28): S146-S151.

• Tyndall A 1997 Hematopoietic stem cell transplantation in rheumatic diseases other than systemic sclerosis and systemic lupus erythematosus. J. Rheumatol. Suppl. 48: 94-97.

• Ureten K, Ertenli I, Ozturk MA, Kiraz S, Onat AM, Tuncer M, Okur H, Akdogan A, Apras S, Calguneri M 2005 Neutrophil CD64 expression in Behcet's disease. J. Rheumatol. 32: 849-852.

• Uskudar O, Akdogan M, Sasmaz N, Yilmaz S, Tola M, Sahin B 2008 Etiology and portal vein thrombosis in Budd-Chiari syndrome. World J. Gastroenterol. 14: 2858-2862. *

• Usui M 2007 Translational research with experimental autoimmune uveoretinitis (EAU). Nippon Ganka Gakkai Zasshi 111: 137-158.

• Utku U, Dilek M, Akpolat I, Bedir A, Akpolat T 2007 SAA1 alpha/alpha alleles in Behcet's disease related amyloidosis. Clin. Rheumatol. 26: 927-929.

• Uyar FA, Saruhan-Direskeneli G, Gul A 2004 Common Crohn's disease-predisposing variants of the CARD15/NOD2 gene are not associated with Behcet's disease in Turkey. Clin. Exp. Rheumatol. 22 (4 Suppl. 34): S50-S52.

• Verity DH, Vaughan RW, Kondeatis E, Madanat W, Zureikat H, Fayyad F, Marr JE, Kanawati CA, Wallace GR, Stanford MR 2000 Intercellular adhesion molecule-1 gene polymorphisms in Behcet's disease. Eur. J. Immunogenet. 27: 73-76.

• Verity DH, Wallace GR, Vaughan RW, Kondeatis E, Madanat W, Zureikat H, Fayyad F, Marr JE, Kanawati CA, Stanford MR 1999 HLA and tumour necrosis factor (TNF) polymorphisms in ocular Behcet's disease. Tissue Antigens 54: 264-272. *

• Wallace GR, Kondeatis E, Vaughan RW, Verity DH, Chen Y, Fortune F, Madanat W, Kanawati CA, Graham EM, Stanford MR 2007 IL-10 genotype analysis in patients with Behcet's disease. Hum. Immunol. 68: 122-127.

• Wallace GR, Verity DH, Delamaine LJ, Ohno S, Inoko H, Ota M, Mizuki N, Yabuki K, Kondiatis E, Stephens HA, Madanat W, Kanawati CA, Stanford MR, Vaughan RW 1999 MIC-A allele profiles and HLA class I associations in Behcet's disease. Immunogenetics 49: 613-617.

• Wallis S, Macierewicz J, Shrestha BM 2006 Behcet's disease: report of a case and review of the literature. JNMA J. Nepal. Med. Assoc. 45: 362-365.

• Wang H, Nakamura K, Inoue T, Yanagihori H, Kawakami Y, Hashimoto S, Oyama N, Kaneko F, Fujita T, Nishida T, Mizuki N 2004 Mannose-binding lectin polymorphisms in patients with Behcet's disease. J. Dermatol. Sci. 36: 115-117.

• Watts RA, Scott DG 2004 Epidemiology of the vasculitides. Semin. Respir. Crit. Care Med. 25: 455-464.

• Wechsler B, Sable-Fourtassou R, Bodaghi B, Huong DL, Cassoux N, Badelon I, Fain O, LeHoang P, Piette JC 2004 Infliximab in refractory uveitis due to Behcet's disease. Clin. Exp. Rheumatol. 22 (4 Suppl. 34): S14-S16.

• Wright V 1979 A unifying concept for the spondyloarthropathies. Clin. Orthop. Relat. Res. 143: 8-14.

• Yabe H, Takano Y, Nomura E, Nakayama M, Kihara M, Miyakawa SI, Horiuchi Y 2008 Two cases of SAPHO syndrome accompanied by classic features of Behcet's disease and review of the literature. Clin. Rheumatol. 27: 133-135. *

• Yabuki K, Mizuki N, Ota M, Katsuyama Y, Palimeris G, Stavropoulos C, Koumantaki Y, Spyropoulou M, Giziaki E, Kaklamani V, Kaklamani E, Inoko H, Ohno S 1999 Association of MICA gene and HLA-B*5101 with Behcet's disease in Greece. Invest. Ophthalmol. Vis. Sci. 40: 1921-1926. *

• Yabuki K, Ohno S, Mizuki N, Ando H, Tabbara KF, Goto K, Nomura E, Nakamura S, Ito N, Ota M, Katsuyama Y, Inoko H 1999 HLA class I and II typing of the patients with Behcet's disease in Saudi Arabia. Tissue Antigens 54: 273-277. *

• Yalcin B, Atakan N, Alli N 2008 The functional role of nuclear factor kappa-kappaB1 -94 ins/del ATTG promotor gene polymorphism in Behcet's disease: an exploratory study. Clin. Exp. Dermatol. Jun 25 [Epub ahead of print]. *

• Yamamoto T, Yokozeki H, Nishioka K 2005 Psoriasis arthropathy and HLA-B51: report of 5 cases. J. Dermatol. 32: 606-610.

• Yanagihori H, Oyama N, Nakamura K, Mizuki N, Oguma K, Kaneko F 2006 Role of IL-12B promoter polymorphism in Adamantiades-Behcet's disease susceptibility: an involvement of Th1 immunoreactivity against Streptococcus sanguinis antigen. J. Invest. Dermatol. 126: 1534-1540. *

• Yang X, Ahmad T, Gogus F, Wallace GR, Madanat W, Kanawati CA, Stanford MR, Fortune F, Jewell DP, Marshall SE 2004 Analysis of the CC chemokine receptor 5 (CCR5) Delta32 polymorphism in Behcet's disease. Eur. J. Immunogenet. 31: 11-14. *

• Yasui K, Uchida N, Akazawa Y, Nakamura S, Minami I, Amano Y, Yamazaki T 2008 Thalidomide for treatment of intestinal involvement of juvenile-onset Behcet disease. Inflamm. Bowel Dis. 14: 396-400.

• Yasuoka H, Okazaki Y, Kawakami Y, Hirakata M, Inoko H, Ikeda Y, Kuwana M 2004 Autoreactive CD8+ cytotoxic T lymphocytes to major histocompatibility complex class I chain-related gene A in patients with Behcet's disease. Arthritis Rheum. 50: 3658-3662. *

• Yavuz S, Elbir Y, Tulunay A, Eksioglu-Demiralp E, Direskeneli H 2008 Differential expression of Toll-like receptor 6 on granulocytes and monocytes implicates the role of microorganisms in Behcet's disease etiopathogenesis. Rheumatol. Int. 28: 401-406. *

• Yazici H, Fresko I 2005 Behcet's disease and other autoinflammatory conditions: what's in a name? Clin. Exp. Rheumatol. 23: S1-S2.

• Yazici H, Fresko I, Yurdakul S 2007 Behcet's syndrome: disease manifestations, management, and advances in treatment. Nat. Clin. Pract. Rheumatol. 3: 148-155. *

• Yazici H, Pazarli H, Barnes CG, Tuzun Y, Ozyazgan Y, Silman A, Serdaroglu S, Oguz V, Yurdakul S, Lovatt GE, et al 1990 A controlled trial of azathioprine in Behcet's syndrome. N. Engl. J. Med. 322: 281-285.

• Yen JH, Tsai WC, Lin CH, Ou TT, Hu CJ, Liu HW 2004 Cytochrome P450 1A1 and manganese superoxide dismutase gene polymorphisms in Behcet's disease. J. Rheumatol. 31: 736-740.

• Yen JH, Tsai WC, Tsai JJ, Chen CJ, Lin CH, Ou TT, Wu CC, Liu HW 1999 HLA-DMA and HLA-DMB genotyping in patients with rheumatic diseases. Kaohsiung J. Med. Sci. 15: 263-267.

• Yeong ML, Bethwaite PB, Prasad J, Isbister WH 1991 Lymphoid follicular hyperplasia - a distinctive feature of diversion colitis. Histopathology 19: 55-61.

• Yesilova Z, Pay S, Oktenli C, Musabak U, Saglam K, Sanisoglu SY, Dagalp K, Erbil MK, Kocar IH 2005 Hyperhomocysteinemia in patients with Behcet's disease: is it due to inflammation or therapy? Rheumatol. Int. 25: 423-428. *

• Yi SW, Kim EH, Kang HY, Kim YC, Lee ES 2007 Erythema nodosum: clinicopathologic correlations and their use in differential diagnosis. Yonsei. Med. J. 48: 601-608. *

• Yokota K, Akiyama Y, Sato K, Shindo Y, Yoshida Y, Miyoshi F, Akiba H, Nakajima K, Asanuma Y, Mimura T 2008 Vasculo-Behcet's disease with non-traumatic subcapsular hematoma of the kidney and aneurysmal dilatations of the celiac and superior mesenteric arteries. Mod. Rheumatol. Jun 18 [Epub ahead of print].

• Yoshikawa H, Kurokawa M, Ozaki N, Nara K, Atou K, Takada E, Kamochi H, Suzuki N 2006 Nicotine inhibits the production of proinflammatory mediators in human monocytes by suppression of I-kappaB phosphorylation and nuclear factor-kappaB transcriptional activity through nicotinic acetylcholine receptor alpha7. Clin. Exp. Immunol. 146: 116-123. *

• Yuksel Z, Schweizer JJ, Mourad-Baars PE, Sukhai RN, Mearin LM 2007 A toddler with recurrent oral and genital ulcers. Clin. Rheumatol. 26: 969-970. *

• Zhao C, Yang P, He H, Lin X, Li B, Zhou H, Huang X, Kijlstra A 2008 S-antigen specific T helper type 1 response is present in Behcet's disease. Mol. Vis. 14: 1456-1464. *

• Zierhut M, Mizuki N, Ohno S, Inoko H, Gul A, Onoe K, Isogai E 2003 Immunology and functional genomics of Behcet's disease. Cell. Mol. Life Sci. 60: 1903-1922. *

• Zuber PJ, Bart AP, Leimgruber A, Spertini F 2008 Behcet's disease: from Hippocrates to TNF-alpha-blockers. Rev. Med. Suisse. 4: 1045-1048, 1050-1054.

Number of references = 386

www psc-literature.org